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Seroprevalence of Severe Acute Respiratory 
Syndrome-Coronavirus-2 Immunoglobulin M and 
Immunoglobulin G Antibodies among the Population 
of Koya University
Abstract–Coronavirus is a pandemic disease. In most cases, 
the exact infection rate cannot be determined as not everybody 
can be tested for the virus, even though some of them carry the 
virus silently. Therefore, detection of antibodies of this virus is 
more practical to give us a better clue about the rate of infection 
because the asymptomatic people can be tested too. The serological 
detection of anti-Severe Acute Respiratory Syndrome-Coronavirus 
(SARS-COV-2) antibodies among asymptomatic and moderate 
symptomatic individuals gives us the vital point to understanding 
the prevalence rate of COVID-19 among the population. Total of 
(436) volunteers were participated, (96) from teaching staff, (172) 
employee, and (168) students. Anti-SARS-COV-2 immunoglobulin 
G (IgG) and Immunoglobulin M (IgM) were detected in the serum 
by ELISA technique, and complete blood count was performed for 
all participants. The number of seropositive of anti-SARS-COV-2/
IgG was (159), whereas IgM was (66). The highest prevalence rate 
of IgG detected among participants with family member infected 
with coronavirus (42.7%). Total WBCs count significantly increased 
among IgM positive participants. Many asymptomatic people 
were infected with coronavirus, which lead to more spreading of 
the virus among the population. Therefore, mass screening of the 
population for specific antibody against coronavirus is important 
to reduce the infection rate.
Index Terms — Anti-severe acute respiratory syndrome-
coronavirus-2 Antibody, Coronavirus, Coronavirus 
disease-19, Immunoglobulin G, Immunoglobulin M.
I. Introduction
COVID-19 is transmissible between humans through nasal 
particles or close contact in both clinical and subclinical 
persons (Lauer, et al., 2020). The first case of COVID-19 
recorded in Iraq, on February 24, 2020, was registered in 
Najaf province for a student who had travelled from Iran, 
followed by four cases of one family members in the Kirkuk 
zone on February 25, all of whom had travelled to Iran, by 
April 16, 2020, the number of reported cases rose to 1415, 
with 78 deaths (Sarhan, et al., 2020).
The serological analysis is available to be applied 
commercially based on Enzyme-linked immunosorbent assay 
(ELISA) and other techniques, mainly designed to examine 
anti-spike (S) and anti-nuclear (N) antibody in the blood that 
synthesized by B-lymphocytes after induced by viral particles 
(S and N) because of their high antigenic properties (Li et 
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As a zoonosis that has spread to several million human beings 
and  probably to domestic and  wild animals,  the world has 
witnessed waves of coronavirus infection threatening the 
global catastrophe of Severe Acute Respiratory Syndrome 
(SARS) in 2002–2003 and Middle East Respiratory 
Syndrome in 2011 (MERS). In both cases, newly described 
coronaviruses of the genus Beta-coronavirus with zoonotic 
origins were causative agents. In Wuhan, Hubei, China, 
an outbreak of another coronavirus that causes pulmonary 
disease has been announced in late of 2019.
The disease officially called Coronavirus Disease 2019 
(COVID-19), SARS-COV-2 (etiological agent of COVID-19) 
genome sequences analysis demonstrated close to the 
genomic structure of both MERS and SARS-COV (Wu, 
et al., 2020; Azkur, et al., 2020). The recent study done by 
Dimonte et al. (2020) illustrated that the phylogenic tree 
analysis by sequencing the amino acids associated with the 
structural proteins of the novel coronavirus (nCOV) almost 
indistinguishable from the SARS-COV, which founded 
among the different area (Dimonte, et al., 2020).
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al., 2005). Anti-S immunoglobulin M (IgM) antibodies can 
be detected in proximity about 5–12 days after the symptoms 
appear among individuals who suffered from COVID-19, 
whereas immunoglobulin G (IgG) and IgA capable of detected 
in the sera of patients after a fortnight (Wölfel, et al., 2020). 
Immunoglobulin detection against SARS-COV-2 in the serum 
samples of individuals shows they had been infected at a 
particular stage during the outbreak. As a result, serologic 
analyses could be used to achieve people-based assessments 
of infection, including individuals who also had asymptomatic 
or moderate illnesses or who were not ever examined although 
having symptoms. Mainly the reported cases focused on 
symptomatic persons and those who have been in contact with 
the confirmed COVID-19 individuals and came back from an 
epidemic area. In general, used reverse transcription-polymerase 
chain reaction (RT–PCR) method for detecting the genome of 
the virus is a highly sensitive technique. Sadly, a vast population 
of asymptomatic and subclinical infected persons cannot 
be diagnosed based on molecular biology strategy (Huang, 
et al., 2020). The existence of anti-SARS-CoV-2 antibodies 
in a community may provide a better realistic prediction of 
the cumulative prevalence of SARS-CoV-2 infection than the 
viral examination because immunoglobulin against the virus, 
predominantly IgG, can persist for a prolonged period after the 
viral infection is eliminated (Xu, et al., 2020).
The benefits of seroprevalence investigation focus on their 
efficiency in evaluating the degree of asymptomatic exposure 
among patients and identifying high-risk classes. The study 
aimed to establish the prevalence of SARS-CoV-2 (IgG and 
IgM) antibodies in Koya University among academic staff, 
employers, and students.
II. Materials And Methods
A. Study design and Participants
This study was performed at Science and Health Research 
center/Koya University/Erbil/Iraq from January 5 to March 
10, 2021. It is a cross-sectional study which involved a 
random selection of (436) participants, (96) from teaching 
staff, (172) employee, and (168) students. Bodyweight was 
one of the parameters represented by body mass index (BMI) 
(BMI=kg/m2 where kg is a person’s weight in kilograms 
and m2 is their height in meters squared). The participants 
classified as smokers according to the WHO’s Smoking and 
Tobacco Use Policy; a smoker is someone who smokes any 
tobacco product, either daily or occasionally.
B. Sample Collection and Examination
We collected 5 ml venous blood, 2 ml were put in a 
lavender tube (Biozek-BE320030) for complete blood count, 
and 3 ml were put in a gel bottom tube (Biozek-BVG419020) 
to obtain serum. The blood in the gel bottom tube was 
centrifuged at (5000 RPM) for 5 min. The obtained serum was 
divided into two-part and stored in a 1.5 ml Eppendorf test 
tube, then preserved at -80 °C in (GLF-6483) and defrosted 
upon testing. Complete Blood Count (CBC) was performed 
using (Mythic 18). COVID-19 IgM and IgG were evaluated 
using (SARS-Cov-2 IgM Capture ELISA kit 96t Cat. No: 
7424-96) and (SARS-Cov-2 IgG Capture ELISA kit 96t 
Cat. No: 7324-96), respectively, according to manufacturer’s 
instruction. The test performed using (BIOTEK-ELX800) 
reader. The result of anti-SARS-COV-2/IgM and IgG was 
calculated using the cutoff index (COI) method. The result 
was marked positive if COI > 1.1 and negative if COI < 0.9.
C. Questionnaire and Statistical Analysis
To determine the seroprevalence of COVID-19 at Koya 
University, a questionnaire was designed. The questionnaire 
was involved asking some categorical (Yes and No) response. 
Analysis of data was performed using Statistical Package for 
the Social Science (SPSS) Version 25.0. Quantitative data, 
the test of significance used for comparing differences in 
means, were made by t-test, whereas for qualitative data, the 
difference in proportions was tested by using Chi-square (X2) 
test. P-value ≤ 0.05 was considered statistically significant.
III. Results
The study was carried out among (436) participants who 
compromised academic staff (22%), employed (39.5%), and 
(38.5) students, and the highest (44.7%) were at the age 
range of (24≤) years. The mean age of the participant was 
(30.61 ± 10.95) years. More than half (64%) were male. 
16.3 had a smoker, and only (4.4%) person consume alcohol. 
The residence was predominantly home (67%), compare to 
accommodation which was (33%), with approximately half 
of them wearing masks regularly (50.5%). Mostly the blood 
group of volunteers was O positive (34.4%) and followed by 
blood group B plus (27.3%). The BMI of 211 participants 
out of the total were normal, whereas (12.8) members of 
participants were obese, shown in Table I.
The highest cases of IgG anti-SARS-COV-2 were detected in 
obese individuals (42.9%), and IgM type antibody found among 
normal body weight (16.6%). The Chi-square analysis shows 
no significant differences (P > 0.05). Table II illustrated that the 
prevalence of IgG antibody significantly higher among people 
who had blood B+ types (50.4%) (P < 0.05). Simultaneously, 
there was a non-significant difference in IgM anti-SARS-
COV-2 antibody among blood groups (P > 0.05). The risk of 
Coronavirus (COVs) infection increased highly significantly 
among participant’s that had a family history infected by 
SARS-COV-2 (42.7%) in comparison to those who did not 
their family members suffered by COVID-19 (P < 0.01).
Furthermore, regularly wearing a face mask reduces the 
rate of transmission of viral infection. The data revealed 
seropositivity of anti-SARS-COV-2 IgG significantly declined 
among individuals who wear a face mask daily (30%), 
(P < 0.01), in comparison to other classes that did not wear it 
on a daily basis was 43.1%. Recent infection of COVs, which 
capable determined by anti-SARS-COV-2 IgM antibody 
significantly lower in participants was (3.1%) who have a 
chronic disease (P < 0.05). There is no significant difference 
in seropositivity prevalence rate in terms of alcohol genders, 
consumption, smoking, and occupations, as shown in Table II.
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t-test explains that, total white blood cells (WBCs) count 
significantly decreased (P < 0.05) in the blood sample 
of seropositive for IgG participants (6.29 ± 1.44*103/
μl) compare to seronegative individuals (6.67 ± 1.61*103/
μl), in contrast, IgM positive blood sample, total WBCs 
counts dramatically increased (7.01 ±1.74 *103/μl) in 
compare to non-detected IgM blood samples, which was 
6.45 ± 1.51*103/μl. Absolute granulocyte counts significantly 
decreased among seropositive IgG individuals whereas 
increased among IgM seropositive samples (P < 0.05), vice 
versa, monocyte and lymphocyte percentage significantly 
reduced during IgG positive and elevated among IgM 
positive blood specimens (P < 0.05). Other blood parameters 
such as total erythrocyte count, hemoglobin concentration, 
platelet count, and indexes show no significant differences 
among blood samples, as shown in Table III.
Among all the samples, the overall of frequency of IgM 
positivity was (15.1%), whereas the IgG was (36.5%), 
whereas only 20 participants (4.6%) were positive for both 
SARS-Cov-2 immunoglobulins, IgG and IgM depending on 
the Cutoff Index (COI) as shown in Table IV.
IV. Discussion
Coronavirus disease 2019 (COVID-19) is a pandemic 
disease which has a significant effect on global economy and 
other sectors of life. Educational institutes form schools to 
universities were obligated by the governments to close their 
doors at the beginning of the pandemic in fear of spreading 
the virus within the community. In Kurdistan, Iraq, Kurdistan 
Regional Government (KRG) put tight restrictions for 
travelers coming to the region and announce safety measures 
and raising awareness for its residence. One of the restriction 
measures was closing all states and private schools and 
universities in the region from February 26 until May 2, 2020 
(Merza, et al., 2020). Koya University was one of the state 
Universities that closed due to the Coronavirus pandemic. 
However, Koya University was the first university to open 
its door on October 4, 2020, after releasing the restrictions 
by the government and brought students to the university 
accommodation and campus.
Since the beginning of COVID-19 outbreaks, many 
questions were asked about controlling the spread of the 
virus; one of the classical ways of controlling any infection in 
the community is by gaining herd immunity, how long does 
it take for the herd immunity to reach the protection level 
this depends on different regions (Britton, Ball and Trapman, 
2020). These results represent the first seroprevalence data 
to be conducted within Kurdistan regional government 
universities in Iraq. However, a larger scale community-
based seroprevalence study will give a better representative 
picture in this area.
In the present study, the overall seroprevalence of anti-
SARS-COV-2 antibodies, IgG and IgM was (36.6%) and 
(15.2%), respectively. Therefore, measuring the amount of 
seropositivity, as recommended by the WHO, will notify the 
proportion of people positive for anti-SARS-CoV-2 antibodies 
in the community and thereby show the transmission rate over 
time (WHO, 2020b). Furthermore, the degree of infection in 
a society depends primarily on communication encounters 
and population size; it is crucial to assess the proportion of 
potentially healthy and protected persons in communities 
with different exposure levels (Shakiba, et al., 2020).
Over 14 day duration, 30-40% among all infected persons 
by SARS-COV-2 are thought to be asymptomatic (Oran 
and Topol, 2020). According to the Centers for Disease 
Control and Prevention, 35% of COVID-19 patients 
are asymptomatic, and 40% of infection happens before 
symptoms appear (CDC and Prevention, 2020). Therefore, 
mass screening aims to determine and isolate victims and 
tracing their associations, which are essential to minimizing 
the spread of coronavirus (Hellewell, et al., 2020).
During this asymptomatic stage of infection specific 
antibody will form against the virus and the first IgM 
antibodies can be detected as early as 3 days after 
infection, which serve as a first line of defense. Then its 
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level will decline, and IgG antibody will form. This will 
make a long-term memory and fight against the virus in 
the future (Racine and Winslow, 2009). Therefore, in our 
data both SARS-COV-2 IgG and IgM antibody detection 
in 20 participants (4.6%) are normal as any other viral 
infection. The presence of both antibodies at the same time 
represents the overlap production of both antibodies during 
microbial infection throughout the course of the disease. 
A study conducted by Nakano et al. in 2021 showed that 
anti- SARS-COV-2 IgM titer would increase until day 18 
after the symptoms appeared, after that it will decline and, 
IgG remains stable above 400AU/ml after day 13, it increases 
afterwards (Nakano, et al., 2021).
The seropositive IgM was significantly higher among 
participants with chronic diseases such as hypertension 
and diabetes (3.1%) (George, et al., 2019) and (42.7%) of 
participants were IgG positive had family members infected 
with COVID-19, which agrees with other research done in 
India (George, et al., 2021) one of the first protective strategies 
against SARS-COV-2 was wearing the mask, the governments 
were asking, or in some order to wear masks, since then 
many researches and public reports showed the significance 
Table II
Association between Socio-demographic Attributes with Anti-SARS-COVID-2 Antibodies
Variables IgG P value IgM P value
Negative Positive Negative Positive
No. % No. % No. % No. %
Gender
Female 97 61.8 60 38.2 0.569 134 85.4 23 14.6 0.83
Male 180 64.5 99 35.5 236 85.6 43 15.4
Age group
24≤ 130 66.7 65 33.3 0.221 161 82.6 34 17.4 0.35
25–34 68 64.5 36 34.6 88 84.6 16 15.4
35≥ 79 57.7 58 42.3 121 88.3 16 11.7
BMI 
Underweight 9 100 0 0.0 0.08 8 88.9 1 11.1 0.538
Normal 131 62.1 80 37.9 176 83.4 35 16.6
Overweight 105 65.6 55 34.4 135 84.4 25 15.6
Obesity 32 57.1 24 42.9 51 91.1 5 8.9
Occupation
Teacher 57 59.4 39 40.6 0.446 82 85.4 14 14.6 0.159
Employed 115 66.9 57 33.1 152 88.4 20 11.6
Student 105 62.5 63 37.5 136 81 32 19
Blood groups
A+ 70 66.7 35 33.3 0.029* 91 86.7 14 13.3 0.69
B+ 59 49.6 60 50.4 105 88.2 14 11.8
O+ 105 70 45 30 122 81.3 28 18.7
AB+ 19 67.9 9 32.1 22 78.6 6 21.4
A- 11 78.6 3 21.4 13 92.9 1 7.1
B- 4 57.1 3 42.9 6 85.7 1 14.3
O- 8 66.7 4 33.3 10 83.3 2 16.7
AB- 1 100 0 0.0 1 100 0 0.0
Residency 
Home 184 63 108 37 0.749 235 86.6 39 13.4 0.139
Accommodation 93 64.6 51 35.4 117 81.3 27 18.8
Family member infected by COVID-19
No 152 69.7 66 30.3 0.007* 187 85.8 31 14.2 0.593
Yes 125 57.3 93 42.7 183 83.9 35 16.1
Chronic diseases
No 257 63.8 146 36.2 0.619 338 83.9 65 16.1 0.03*
Yes 19 59.4 13 40.6 31 96.9 1 3.1
Wearing Mask
No 123 56.9 93 43.1 0.003* 182 84.3 34 15.7 0.72
Yes 154 70 66 30 188 85.5 32 14.5
Smoking
No 225 61.6 140 38.4 0.063 309 84.7 56 15.3 0.78
Yes 52 73.2 19 26.8 61 85.9 10 14.1
Alcoholism 
No 264 63.3 153 36.7 0.425 325 84.4 65 15.6 0.18
Yes 13 68.4 6 31.6 18 94.7 1 5.3
Total 277 63.4 159 36.6 369 84.4 66 15.2
* Indicate significant levels (P≤0.05)
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of wearing the mask in decreasing the transmission of the 
virus as this may help in reducing the direct contact with 
the droplets of an infected person (Howard, et al., 2020). 
In our finding, the seropositive IgG of SARS-COV-2 was 
significantly lower among participants wearing mask daily 
(30%) (P < 0.01) in comparison to those not wearing a mask 
on a daily basis (43.1%), which mean good protection against 
virus transmission, this result is compatible with many other 
researches done regarding the efficiency of wearing a mask in 
reducing virus transmission. A study by Leffler et al. (2020) 
comparing the effect of wearing a mask in different countries, 
they found that the transmission of the virus was 7.5% higher 
in countries wearing a mask was not compulsory.
The relationship between blood group and microbial 
infection has been documented previously (Leffler, et al., 
2020). This relation was connected to the difference in 
antigens found in erythrocytes that react differently with 
different bacteria, parasites and viruses (Acik and Bankir, 
2021); this can be true for SARS-COV-2 infection as well. 
The results of our study showed that the highest seropositive 
IgG was found among B+ blood group participants (50.4%) 
who disagree with (Pourali, et al., 2020). Our result, similar 
to other researches, showed that the blood group O+ was 
more resistant to SARS-COV-2 infection (30%) (Wu, et al., 
2020; Zhao, et al., 2020; Acik and Bankir, 2021).
Since the onset of COVID-19, many factors were connected 
to the severity and mortality rate among infected people, for 
example, chronic disease cardiovascular diseases and diabetes, 
age and gender (Guzik, et al., 2020; Teng, et al., 2020). 
Moreover, WBC count is one of the factors that have been 
linked to COVID-19 infection severity and mortality. Possibility 
of death will be higher in COVID-19 patients with elevated 
WBC count (Zhu, et al., 2021). Increase total WBC count and 
neutrophils, decreased lymphocyte count has reported in many 
studies about COVID-19. However, other studies in the same 
field reported different and variable results regarding the WBC 
profile of COVID-19 patients (Sun, Zhou and Ye, 2021). These 
inconsistence in the results of WBC in Coronavirus infected 
people make it difficult to connect it to the severity of the 
disease or use it as a prognosis tool, since this difference or 
changes in the WBC counts are strongly related to the immune 
system and variability in immune response within people 
(Siedlinski, et al., 2020; Sun, Zhou and Ye, 2021).
As a result of the importance of the WBCs in establishing 
the immune response and inflammation, it is used as 
a parameter in determining the severity of COVID-19 
infection and increased risk of mortality (Wang, et al., 2021). 
Coronavirus infection, as any other infection, is companied 
by immune response and inflammation, which indicated 
by many inflammatory markers in the body, including 
inflammatory cytokines and WBCs. The results of our study 
showed increased total WBC in IgM positive or recent 
infection (P > 0.01), which agree with the meta-analysis 
review study done by Feng, et al., 2020. However, there was 
no significant difference between infected and non-infected 
participants regarding total lymphocytes and monocytes.
On the other hand, our data showed significant reduction 
in total WBC among seropositive IgG participants compared 
with seronegative individuals (P > 0.05) which agree with 
a study contacted by Liu et al. (2020), demonstrating that 
approximately 80% of the patients suffered from COVID-19 
had a normal or reduced WBC counts. Lymphocytes levels 
were low in 72.3 percent (Liu, et al., 2020). By studying 
the relation between coronaviruses infection and the innate 
immune response, the possibility of persisting and developing 
of chronic inflammation among these population will be 
more clear (Zhu, et al., 2021).
Table III
Comparison of Blood Cell Parameters in Seroprevalence of Anti-SARS-COV-2
Blood parameters IgG (Mean±SD) P 
value
IgM (Mean±SD) P 
valuePositive n (159) Negative n (277) Positive n (66) Negative n (369)
WBC (103/μl) 6.29±1.44 6.67±1.61 0.014* 7.01±1.74 6.45±1.51 0.007*
LYM (103/μl) 1.9±0.47 1.89±0.55 0.865 1.95±0.43 1.88±0.54 0.368
MON (103/μl) 0.397±0.18 0.4±0.18 0.66 0.38±0.15 0.4±0.19 0.465
GRA (103/μl) 3.99±1.21 4.37±1.41 0.004* 4.67±1.59 4.15±1.29 0.004*
LYM% 30.98±7.31 29.05±7.5 0.009* 28.77±6.96 29.93±7.56 0.264
MON% 6.38±2.76 6.2±2.79 0.517 5.64±2.24 6.38±2.85 0.021*
GRA% 62.81±7.31 64.77±8.05 0.012* 65.58±7.37 63.79±7.89 0.087
RBC (106/μl) 5.33±2.89 5.18±0.612 0.434 5.3±0.736 5.22±1.94 0.744
HGB (g/dl) 14.8±1.99 15±1.94 0.175 15.08±1.8 14.95±1.99 0.618
HCT (%) 44.4±4.57 44.95±5.21 0.268 45.48±4.2 44.61±5.11 0.195
MCV 87.47±7.47 87.08±8.16 0.628 86.68±8.73 87.32±7.76 0.542
HCH (pg) 29.27±3.36 29.32±3.53 0.897 28.79±4.0 29.39±3.36 0.195
MCHC (g/dl) 33.47±2.4 33.52±2.63 0.847 33.15±2.46 33.57±2.56 0.225
RDW 12.81±1.25 12.86±2.32 0.810 12.7±1.34 12.85±2.1 0.765
PLT 245.13±74.4 245.87±54.4 0.904 246.61±54.54 245.42±63.76 0.887
PDW 15.05±1.32 15.13±1.414 0.544 14.92±1.182 15.13±1.41 0.259
* indicate significant levels (P≤0.05)
Table IV
Frequency anti-SARS-CoV-2 Immunoglobulins among participants
Anti-SARSCoV-2 Positive Negative
IgM 66 (15.1%) 370 (84.9%)
IgG 159 (36.5%) 277 (63.5%)
IgM and IgG 20 (4.6%) 416 (95.4%)
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In most COVID-19 seroprevalence assessments up to date, 
the cumulative rate of infection was identified primarily 
by age group, race, ethnicity, and nationality. Antiviral 
IgG screening of people in high-risk jobs to COVs due to 
repeated or high social activities could be needed for public 
health decisions on immediate lockdowns or return to work 
policies (WHO, 2020a; Bendavid, et al., 2021; Rosenberg, 
et al., 2020).
V. Conclusion
Many people in the community are infected with 
coronavirus without any symptoms, which has a bigger 
threat on spreading the virus to a non-infected person. The 
previous infected asymptomatic individuals can be detected 
just by antibody testing, giving a clear picture of the rate 
of COVID-19 infection among the population. This figure 
could be used to assist the health sectors in confirming 
better identify infection, death rates and make policy 
decisions. Based on the studied samples from people at Koya 
University, we recommend that the analyses with a vast 
sample size yield more reliable estimation of the proportion 
that has historically been infected with SARS-COV-2 and, as 
a result, provide more detailed information on herd immunity.
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